Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Total Non-Current Liabilities: 2016-2025

Historic Total Non-Current Liabilities for Ultragenyx Pharmaceutical (RARE) over the last 9 years, with Sep 2025 value amounting to $410.6 million.

  • Ultragenyx Pharmaceutical's Total Non-Current Liabilities rose 15.70% to $410.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $410.6 million, marking a year-over-year increase of 15.70%. This contributed to the annual value of $421.3 million for FY2024, which is 19.27% up from last year.
  • Per Ultragenyx Pharmaceutical's latest filing, its Total Non-Current Liabilities stood at $410.6 million for Q3 2025, which was up 12.41% from $365.2 million recorded in Q2 2025.
  • In the past 5 years, Ultragenyx Pharmaceutical's Total Non-Current Liabilities ranged from a high of $421.3 million in Q4 2024 and a low of $196.2 million during Q2 2021.
  • Over the past 3 years, Ultragenyx Pharmaceutical's median Total Non-Current Liabilities value was $353.3 million (recorded in 2023), while the average stood at $349.3 million.
  • In the last 5 years, Ultragenyx Pharmaceutical's Total Non-Current Liabilities plummeted by 33.05% in 2021 and then spiked by 44.53% in 2022.
  • Ultragenyx Pharmaceutical's Total Non-Current Liabilities (Quarterly) stood at $248.1 million in 2021, then climbed by 28.00% to $317.5 million in 2022, then climbed by 11.26% to $353.3 million in 2023, then grew by 19.27% to $421.3 million in 2024, then climbed by 15.70% to $410.6 million in 2025.
  • Its Total Non-Current Liabilities was $410.6 million in Q3 2025, compared to $365.2 million in Q2 2025 and $366.6 million in Q1 2025.